
BridgeBio Pharma, Inc. (BBIO) climbs 11% on ATTR-CM news
BridgeBio Pharma, Inc. (BBIO) climbs after hours as a rival ATTR-CM therapy suffers a late-stage setback, improving the outlook for Attruby. The move comes on top of strong sales momentum, fresh financing flexibility, and bullish analyst support, giving the rally more substance than a typical trading pop.










